Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Urology"
DOI: 10.1097/01.ju.0000614704.30826.9b
Abstract: available at http://www.ncbi.nlm.nih.gov/pubmed/31340094 Editorial Comment: This open-label phase 2 study examined the impact of oral erdafitinib, a tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) 1 through 4, in patients with locally advanced/unresectable or… read more here.
Keywords: locally advanced; carcinoma; fgfr alterations; urothelial carcinoma ... See more keywords
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-2664
Abstract: Abstract Purpose: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (BGJ398), in… read more here.
Keywords: fgfr alterations; recurrent gliomas; patients recurrent; phase study ... See more keywords
TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps3156
Abstract: TPS3156 Background: Approximately 7% of advanced solid malignancies have FGFR gene alterations. However, standard treatment for FGFR-altered malignancies has not been established. Moreover, circulating tumor DNA (ctDNA) analysis has a potential to accurately identify FGFR… read more here.
Keywords: fgfr alterations; advanced solid; malignancies fgfr; tas 120 ... See more keywords